Publication | Closed Access

Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma

Hematological MalignancyOncologyRelapsed–refractory Multiple MyelomaHematologyMyeloid NeoplasiaConsolidation/maintenance TherapyPharmacotherapyMedicineRadiation OncologyHealth Sciences